Key Drivers
- Positive EBITDA
- Improved liquidity
- Intangible concentration
AIAI Summary
NEOG's investment thesis has shifted from acquisitive growth to a high‑execution turnaround where the stock will only re-rate if management converts recent positive quarterly EBITDA and FCF into several consecutive, sustainable quarters of cash generation while materially reducing net debt—critical catalysts are a successful PetriFilm production transfer (to stop scrap/write-offs) and timely deleveraging using divestiture proceeds. If those operational fixes and working‑capital improvements fail or cash generation falters, the company remains exposed to impairment, interest‑coverage stress, and further downside; investors should watch consecutive quarters of EBITDA/FCF and debt reduction as go/no‑go signals.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Positive EBITDA
- •Improved liquidity
- •Intangible concentration
NEOG's latest quarter shows clear operational stabilization with positive EBITDA, improving liquidity and free cash flow, but remains constrained by prior-year scale losses, large intangibles and mixed solvency that weigh on valuation.
Price Behavior
Key Price Behavior Insights:
- •Downtrend momentum
- •Support turned resistance
- •Mean-reversion risk
NEOG is in a clear downtrend after dropping ~26% last month from $11.33 to $8.36, breaking $9.65–$9.70 support (now potential resistance) and leaving downside risk until price reclaims $9.70+ for confirmation.
Rapid ~26% decline from $11.33 to $8.36 last month, raising short-term bounce potential
Sentiment & News
Key News Insights:
- •Genomics sale
- •Mixed sentiment
- •Active repositioning
Neogen is simplifying its portfolio by selling its global genomics unit to Zoetis for $160M, prompting mixed analyst sentiment and active institutional repositioning.
The divestiture narrows Neogen's focus and should prompt near-term revaluation as investors and analysts reassess growth and margin prospects
Similar Companies in Healthcare
Other companies in the same sector with AI ratings